Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors.
Pierre Fumoleau
Consultant or Advisory Role - Debiopharm Group
Jean-Charles Soria
No relevant relationships to disclose
Jean-Pierre Delord
Consultant or Advisory Role - Debiopharm Group
Riccardo Belli
Employment or Leadership Position - Debiopharm Group
Silvano Brienza
Employment or Leadership Position - Debiopharm Group
Claudio Zanna
Employment or Leadership Position - Debiopharm Group
Alice Destaillats
Employment or Leadership Position - Debiopharm Group
Consultant or Advisory Role - Debiopharm Group
Elisabeth Rouits
Employment or Leadership Position - Debiopharm Group
Antoine Hollebecque
No relevant relationships to disclose
Anas Gazzah
No relevant relationships to disclose
Nicolas Isambert
No relevant relationships to disclose